Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $52.2 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 17.62% to $52.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.2 million through Dec 2025, down 17.62% year-over-year, with the annual reading at $52.2 million for FY2025, 17.62% down from the prior year.
  • Total Non-Current Liabilities hit $52.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $53.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $96.4 million in Q1 2021 to a low of $42.2 million in Q4 2021.
  • Historically, Total Non-Current Liabilities has averaged $56.7 million across 5 years, with a median of $55.9 million in 2023.
  • Biggest YoY gain for Total Non-Current Liabilities was 41.0% in 2022; the steepest drop was 55.93% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $42.2 million in 2021, then skyrocketed by 41.0% to $59.5 million in 2022, then grew by 18.99% to $70.8 million in 2023, then fell by 10.6% to $63.3 million in 2024, then fell by 17.62% to $52.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RCKT at $52.2 million in Q4 2025, $53.3 million in Q3 2025, and $65.7 million in Q2 2025.